Abstract
Multidrug resistance has became the major obstacle to cancer chemotherapy. Recent studies suggest that quercetin could enhance the response of tumors to chemotherapy although the mechanism by which quercetin enhances the sensitivity of tumor cells to chemical drugs remains elusive. Therefore, in this study, we examined the effects of quercetin on doxorubicin cytotoxicity in human breast cancer cells and investigated the underlying mechanisms. MCF-7 and MCF-7/ dox cells were exposed to doxorubicin, quercetin, or combination of both agents for 36 hours. Cell proliferation, cell invasion, intracellular doxorubicin concentration and expression of hypoxia-inducible factor-1 alpha (HIF-1α) and P-glycoprotein (P-gp) were then assessed. Quercetin had little effect on cell proliferation at concentrations less than 0.7 μM. Compared to treatment with doxorubicin alone, combined treatment with doxorubicin and quercetin (0.7 μM) significantly inhibited cell proliferation and invasion and suppressed the expression of HIF-1α and P-gp. Quercetin (0.7 μM) increased the intracellular doxorubicin concentration and enhanced doxorubicin cytotoxicity as 1.49-fold in MCF-7 cells and 1.98-fold in MCF-7/dox cells. These data suggest that quercetin can increase the chemosensitivity of breast cancer cells to doxorubicin.
Keywords: Doxorubicin, Quercetin, Chemotherapy, Cytotoxicity
Anti-Cancer Agents in Medicinal Chemistry
Title:The Effect of Quercetin on Doxorubicin Cytotoxicity in Human Breast Cancer Cells
Volume: 13 Issue: 2
Author(s): Shi-zheng Li, Kun Li, Jun-hua Zhang and Zhe Dong
Affiliation:
Keywords: Doxorubicin, Quercetin, Chemotherapy, Cytotoxicity
Abstract: Multidrug resistance has became the major obstacle to cancer chemotherapy. Recent studies suggest that quercetin could enhance the response of tumors to chemotherapy although the mechanism by which quercetin enhances the sensitivity of tumor cells to chemical drugs remains elusive. Therefore, in this study, we examined the effects of quercetin on doxorubicin cytotoxicity in human breast cancer cells and investigated the underlying mechanisms. MCF-7 and MCF-7/ dox cells were exposed to doxorubicin, quercetin, or combination of both agents for 36 hours. Cell proliferation, cell invasion, intracellular doxorubicin concentration and expression of hypoxia-inducible factor-1 alpha (HIF-1α) and P-glycoprotein (P-gp) were then assessed. Quercetin had little effect on cell proliferation at concentrations less than 0.7 μM. Compared to treatment with doxorubicin alone, combined treatment with doxorubicin and quercetin (0.7 μM) significantly inhibited cell proliferation and invasion and suppressed the expression of HIF-1α and P-gp. Quercetin (0.7 μM) increased the intracellular doxorubicin concentration and enhanced doxorubicin cytotoxicity as 1.49-fold in MCF-7 cells and 1.98-fold in MCF-7/dox cells. These data suggest that quercetin can increase the chemosensitivity of breast cancer cells to doxorubicin.
Export Options
About this article
Cite this article as:
Li Shi-zheng, Li Kun, Zhang Jun-hua and Dong Zhe, The Effect of Quercetin on Doxorubicin Cytotoxicity in Human Breast Cancer Cells, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (2) . https://dx.doi.org/10.2174/1871520611313020020
DOI https://dx.doi.org/10.2174/1871520611313020020 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment
Current Pharmaceutical Design The Applications of Biomarkers in Early Clinical Drug Development to Improve Decision-Making Processes
Current Clinical Pharmacology Adhesion Molecules and Kinases Involved in γ δ T Cells Migratory Pathways:Implications for Viral and Autoimmune Diseases
Current Medicinal Chemistry Reversion of Multidrug Resistance in Tumor By Biocompatible Nanomaterials
Mini-Reviews in Medicinal Chemistry Stress-Activated MAP Kinase Cascades in Cellular Senescence
Current Medicinal Chemistry Radiotherapy in Transitional Cell Carcinoma of Urinary Bladder Cancer –Where Does it Fit Into Treatment Protocol
Current Cancer Therapy Reviews Hormone-Biological Therapy in Breast Cancer: Preclinical Evidence,Clinical Studies and Future Directions
Current Cancer Drug Targets Overview of Protein Kinase B Enzyme: A Potential Target for Breast and Prostate Cancer
Current Molecular Pharmacology 99mTc-labeling of Peptidomimetic Antagonist to Selectively Target αvβ3 Receptor-Positive Tumor: Comparison of PDA and EDDA as Co-Ligands
Current Radiopharmaceuticals Neurochemical and Neuropharmacological Aspects of Circadian Disruptions: An Introduction to Asynchronization
Current Neuropharmacology Quantitative Structure-Activity Relationship Studies: Understanding the Mechanism of Tyrosine Kinase Inhibition
Current Enzyme Inhibition Targeting the Nucleus: An Overview of Auger-Electron Radionuclide Therapy
Current Drug Discovery Technologies Targeting the Ribosome Biogenesis Key Molecule Fibrillarin to Avoid Chemoresistance
Current Medicinal Chemistry Molecular Targeting of Lymphatics for Therapy
Current Pharmaceutical Design α,β-Acetylenic Amino Thiolester Inhibitors of Aldehyde Dehydrogenases 1&3: Suppressors of Apoptogenic Aldehyde Oxidation and Activators of Apoptosis
Current Medicinal Chemistry Box-Behnken Design Optimized TPGS Coated Bovine Serum Albumin Nanoparticles Loaded with Anastrozole
Current Drug Delivery Tumor Necrosis Factor Inhibitors in Pediatric Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Meet Our Associate Editor
Anti-Cancer Agents in Medicinal Chemistry Contemporary Treatment of Amyloid Heart Disease
Current Pharmaceutical Design Metallodrug Conjugates with Steroids and Selective Estrogen Receptor Modulators (SERM)
Current Medicinal Chemistry